Incanthera plc

About Incanthera plc

The Company is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions. The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and is currently being prepared for licensing to a commercial partner within 12-18 months. The Company originated from the Institute of Cancer Therapeutics – University of Bradford and, in addition to Sol, has acquired and developed a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.<p>